Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT04161755
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
  • RO7198457 — BIOLOGICAL
    RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
  • mFOLFIRINOX — DRUG
    mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)

Study Details

The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.

Key Dates

Start date
Dec 13, 2019
Status verified
Jan 2026
Primary completion
Nov 11, 2026
Completion
Nov 11, 2026

Study Design

Enrollment
29 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pancreatic Cancer
    Radiologically resectable primary pancreatic tumors

Primary Outcome Measure

Drug related toxicity [ Time Frame: 2 years ]

Locations (7)

Find similar trials in Basking Ridge, NJ

By condition

Related Studies